Announcement of a Newly Identified Synthetic Cannabinoid
4-CN-AMB-BUTINACA – December 17, 2020

The U.S. Drug Enforcement Administration (DEA) in collaboration with the University of California San Francisco Clinical Toxicology and Environmental Biomonitoring (CTEB) Laboratory has identified a new synthetic cannabinoid, 4-CN-AMB-BUTINACA (4-CYANO-AMB-BUTINACA), in urine samples submitted to our New Psychoactive Substances (NPS) surveillance program.

**Cohort:** In October 2020, prisoners under a work release program from Alabama who were suspected to be using tianeptine and the suspected synthetic cannabinoid-laced drug product, “No Show”

**Drugs Detected:** Tianeptine and the new synthetic cannabinoid, 4-CN-AMB-BUTINACA, were confirmed and quantified in a majority of the samples. Other substances detected in some of the samples include cathinones (NRG-3 and N-ethylbuphedrone (NEB)), and amphetamines (ethylamphetamine and PMMA).

**4-CN-AMB-BUTINACA:** This new synthetic cannabinoid is related to 4-CN-CUMYL-BUTINACA (4-CN-CUMYL-BINACA), a synthetic cannabinoid placed in Schedule I by the DEA on July 13, 2020. 4-CN-CUMYL-BUTINACA has been reported to be a potent cannabinoid receptor 1 (CB1) agonist ($K_i= 2.6 \text{ nM;} \ EC_{50} = 0.58 \text{ nM}$) and is implicated in intoxication cases by the UCSF CTEB Lab and other groups in Turkey and Europe.6,7

**Analysis:** 4-CN-AMB-BUTINACA was detected, confirmed and quantified in urine samples using liquid chromatography- quadrupole time-of-flight mass spectrometry. Details of the method used along with the chromatogram and mass spectra associated with the compound are presented in the attached supporting documents.

**Reference Standard:** As of the date of this release, there is currently no commercially available reference standard for 4-CN-AMB-BUTINACA. A reference standard of the compound was synthesized by our program collaborator at the University of Sydney, Dr. Samuel Banister. The compound is part of the “prophetic” cannabinoids library proactively synthesized to allow our surveillance to identify and confirm previously unreported NPS in real time. The chemical characterization of the reference standard was performed by Mr. Eric Sparkes and Dr. Adam Ametovski and is detailed in the attached supporting documents.

**Pharmacological Data:** Dr. Elizabeth Cairns and Ms. Charlotte Fletcher at the University of Sydney have collected preliminary pharmacological data on 4-CN-AMB-BUTINACA. Using a fluorescence-based imaging plate reader assay in AtT-20 cells stably transfected with human CB1 or CB2 receptors, 4-CN-AMB-BUTINACA (10 µM) elicited 99.7% ± 2.4% and 84.5% ± 3.6% of the maximal normalized response at human CB1 and CB2, respectively (n=3–4), confirming cannabinoid receptor agonist activity. A comprehensive pharmacological characterization of the compound is currently being conducted.

---

1 NRG-3 [2-(methylamino)-1-(naphthalen-2-yl)pentan-1-one]
2 PMMA [1-(4-methoxyphenyl)-N-methylpropan-2-amine; para-methoxymethamphetamine]
3 Drug Enforcement Administration (DEA). Schedules of Controlled Substances: Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA in Schedule I. July 13, 2020. (Federal Register 85, Number 134)
I. General Information

**Synonyms:** 4-CN-MMB-BUTINACA; AMB-4CN-BUTINACA; MMB-4CN-BUTINACA

**IUPAC Name:** methyl (S)-2-(1-(4-cyanobutyl)-1H-indazole-3-carboxamido)-3-methylbutanoate

**InChI String:** InChI=1S/C19H24N4O3/c1-13(2)16(19(25)26-3)21-18(24)17-14-9-5-6-10-15(14)23(22-17)12-8-4-7-11-20/h5-6,9-10,13,16H,4,7-8,12H2,1-3H3,(H,21,24)/t16-/m0/s1

**InChI Key:** WROCSMZNSLKYDI-INIZCTEOSA-N

**SMILES:**
O=C(N[C@@H](C(C)C)C(OC)=O)C1=NN(CCCCC#N)C2=C1C=CC=C2

**CAS Number:** Not available

**CFR:** Not scheduled (12/2020)

II. Physical Properties

**Melting Point:** 141–143 °C

III. Chemical Characterization

**FTIR Spectrum:** $\nu_{\text{max}}$ 2955, 1530, 1507, 1467, 1396, 1278, 1233, 1200, 1148, 1111, 992, 811, 749, 599, 563, 506 cm$^{-1}$

**$^1$H NMR Spectrum:** (400 MHz, CD3OD) $\delta$ 8.22 (dd, $J = 8.3, 1.3$ Hz, 1H), 7.69 (d, $J = 8.9$ Hz, 1H), 7.53 – 7.46 (m, 1H), 7.34 – 7.28 (m, 1H), 4.66 – 4.56 (m, 3H), 3.80 (d, $J = 1.3$ Hz, 3H), 2.52 (t, $J = 7.0$ Hz, 2H), 2.33 (h, $J = 6.7$ Hz, 1H), 2.19 – 2.09 (m, 2H), 1.74 – 1.63 (m, 2H), 1.06 (dd, $J = 6.9, 1.2$ Hz, 6H), NH not observed (exchangeable).
$^{13}$C NMR Spectrum: (101 MHz, CD3OD) $\delta$ 173.6 (CO), 164.6 (CO), 142.4 (quat.), 137.7 (quat.), 128.2 (CH), 123.99 (CH), 123.96 (quat.), 123.1 (CH), 120.8 (CN), 111.0 (CH), 58.7 (CH), 52.7 (OCH3), 49.4 (NCH2), 32.3, 29.7, 23.9, 19.6 (CH3), 18.6 (CH3), 17.0 (CH2).
IV. LC-QTOF/MS Analysis

**Instrument:** Agilent 1260 Infinity, Agilent 6550 QTOF-MS/MS

**Sample Preparation:** Enzymatic deconjugation with *H. pomatia* glucuronidase followed by dilution

**Chromatography**

*Column:* Agilent Poroshell 120 EC-C18 (100 mm x 2.1 mm, 2.7 μm)

*Column Temperature:* 50 °C

*Injection Volume:* 2.5 μL

*Mobile Phase:* A: Ammonium formate (5 mM) and Formic Acid (12.6 mM) in H₂O  
B: Formic Acid (12.6mM) in acetonitrile

*Flow rate:* 0.5 mL/min

*Elution Profile:* Gradient- 95A:5B initially; 70A:30B from 0.5 to 1.5 min; 30A:70B from 1.5 to 4.5 min; 0A:100B from 4.5 to 7.5min; 95A:5B from 10.0 to 14.0 min

*Run Time:* 12 min

**Mass Spectrometry**

*Ion Source:* Dual Jet Stream Electrospray Ionization

*Polarity:* Positive

*TOF MS Scan Range:* 75-1000 Da

*MS/MS Scan Range:* 50-510 Da

*Gas Temperature:* 225 °C

*Drying Gas Flow Rate:* 14L/min

*Sheath Gas Temperature:* 350 °C

*Sheath Gas Flow Rate:* 11L/min

*Nebulizer pressure:* 14psi

*Capillary Voltage:* 3000 V

*Nozzle Voltage:* 500 V

*Skimmer Voltage:* 65 V

*Octopole RF:* 750 V

*Fragmentor Voltage:* 380 V

*Internal Reference Masses:* Purine at m/z 121.0509; HP-921 at m/z 922.0098

*Data Acquisition:* 2GHz, extended dynamic range

*Fragmentation:* Auto MS/MS, three maximum precursors (threshold: 500 counts) per cycle with active exclusion after 1 spectrum at a 30s release time
Extracted Ion Chromatogram

Retention Time: 6.143 min

TOF-MS Spectrum

Exact Mass: 356.1850

Accurate Mass: $[\text{M+H}]^+ = 357.1992$ (mass error=0.48ppm); $[\text{M+Na}]^+ = 379.1743$ (mass error= 0.54ppm)
In response to the ongoing synthetic drug epidemic, the Drug Enforcement Administration (DEA) has initiated a contract with the University of California at San Francisco (UCSF) whereby biological samples generated from overdose victims of synthetic drugs can be further analyzed. In many cases, it can be difficult to ascertain the specific substance responsible for the overdose. We invite medical and law enforcement facilities to contact our program if you encounter an overdose of a suspected synthetic drug and desire to have any leftover biological samples (blood preferred) analyzed further for such synthetic substances.

- **Sample Qualifications:**
  - Patients thought to have ingested a synthetic drug, where the remainder of the drug screen has produced little or no viable options to explain the symptoms exhibited by the patient (alcohol and THC are exempted)

- **How to Contact Us and Send Your Samples:**
  - Once the above qualifications are satisfied:
    - Email DEATOX@USDOJ.GOV with a brief description of the case (including initial toxicology screen and history) and a request for testing.
    - If your request is approved by DEA, we will send instructions for packing and shipping your sample to UCSF.
      - The main reason for disapproval of a case would be the identification of substances including methamphetamine, heroin, fentanyl, cocaine, LSD, PCP etc. in a routine toxicology screening at your facility.
      - This program’s goal is to connect symptom causation to abuse of newly emerging synthetic drugs (e.g. synthetic cannabinoids, synthetic cathinones, fentanyl-related substances, other hallucinogens etc.).
    - Ensure that you de-identify and label the sample with a numerical value, sex, date of birth or age, and the date and time the sample was collected in accordance with the labeling instructions (sent with shipping instructions).
    - Keep a master list of the patients and the numerical values you allocated to each sample at your institution.

- **Cost of sample analysis:**
  - DEA will cover the full cost of testing the patient samples.
  - The sender will only be responsible for paying for packing and shipping samples to UCSF.

- **Turn-around Time:**
  - Results are expected within three weeks of receipt of the sample at UCSF except in rare occurrences when a novel substance is identified.

- **For more information:** [https://www.deadiversion.usdoj.gov/dea_tox/index.html](https://www.deadiversion.usdoj.gov/dea_tox/index.html)